SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jeffrey S. Mitchell who wrote (3404)10/23/1998 9:10:00 PM
From: David K.  Read Replies (2) of 4028
 
Monday may be interesting

CYGS Initiates Antisense Animal Studies
October 23, 1998 06:45 PM

HOUSTON--(BUSINESS WIRE)--Oct. 23, 1998--Cryogenic Solutions Inc. CYGS announced it has recently entered into an agreement with the Southwest Foundation for Biomedical Research to undertake animal testing of its proprietary ssDNA expression vector. The tests will be conducted by Dr. Jason T. Kimata and supervised by Dr. Jean L. Patterson, chairman of the Department of Virology and Immunology. The animal studies are intended to demonstrate the ability of the ssDNA expression vector to synthesize pharmacologically significant titers of sequence specific, antisense competent oligodeoxyribonucleotides intracellularly in an animal model. "We expect to show in a primate that we have overcome the oligo delivery barrier and with controllable expression of ssDNA," said company president, Laurence Mealey. Tests will commence in late November. In addition the company announced plans to begin shipping ssDNA expression vector kits in late November. The kits will be provided to researchers for experimental purposes only and are governed by Materials Transfer Agreements between CYGS and the research facilities. A number of premiere universities and hospitals have requested such agreements to date. The agreements cover commercialization of all discoveries and developments resulting from the use of the company's technology. CYGS is also entertaining overtures from a number of major pharmaceutical companies.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News